Biogen Stock Price and Value Analysis

Should you buy Biogen stock? (NasdaqGS:BIIB). Let's see how it does in our automated value investing analysis system.

BIIB Free Cash Flow Trend

Free Cash Flow trendline for BIIB
Free Cash Flow trendline for Biogen

Based on historical returns, we believe that Biogen can grow its free cash at a rate of about 4%. That's positive!

  • This company is very stable.
  • This company has stable growth.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company pays no dividend.

Inside the BIIB Numbers

BIIB Price
(Biogen stock price per share)
[?] BIIB Fair Price
(based on intrinsic value)
[?] BIIB Safety Price (based on a variable margin of safety) $156.54
[?] PE Ratio versus Sector 57% lower than other Healthcare stocks
[?] PE Ratio versus Industry 49% lower than other Drug Manufacturers - Major stocks
[?] Cash Yield 8.52%
[?] Free Cash Flow Jitter 23%

Is Biogen Stock on Sale?

We believe that Biogen may be worth examining further. It's making money, which is a very positive sign. Is it on sale?

Biogen looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.

Should You Buy BIIB Stock?

Does Biogen have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.